Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study

References

• Giannini EG. Review article: Thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006;23:1055–1065
   PubMed Web of Science ®Google Scholar
• Poordad F. Review article: Thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther 2007;26 Suppl 1:5–11
   PubMed Web of Science ®Google Scholar
• Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B, Esteban R. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008;48:1000–1007
   PubMed Web of Science ®Google Scholar
• Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000;95:2936–2939
   PubMed Web of Science ®Google Scholar
• Giannini E, Botta F, Borro P, Risso D, Romagnoli P, Fasoli A, Mele MR, Testa E, Mansi C, Savarino V, et al. Platelet count/spleen diameter ratio: Proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut 2003;52:1200–1205
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Thulstrup AM, Mellemkjar L, Jepsen P, Christensen E, Olsen JH, Vilstrup H. Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: A nationwide cohort study in Denmark. J Clin Epidemiol 2003;56:88–93
   PubMed Web of Science ®Google Scholar
• D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006;44:217–231
   PubMed Web of Science ®Google Scholar
• Kim SU, Lee JH, Kim do Y, Ahn SH, Jung KS, Choi EH, Park YN, Han KH, Chon CY, Park JY. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One 2012;7:e36676
   PubMed Web of Science ®Google Scholar
• Allegra A, Penna G, Alonci A, Granata A, D'Angelo A, Musolino C. Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B. Med Oncol 2010;27:912–914
   PubMed Web of Science ®Google Scholar
• McCullough J. Current issues with platelet transfusion in patients with cancer. Semin Hematol 2000;37:3–10
   PubMed Web of Science ®Google Scholar
• Perrotta PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Rev 2001;15:69–83
   PubMed Web of Science ®Google Scholar
• Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, McCullough JJ, McIntyre RE, et al. Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1519–1538
   PubMed Web of Science ®Google Scholar
• Hashizume M, Tomikawa M, Akahoshi T, Tanoue K, Gotoh N, Konishi K, Okita K, Tsutsumi N, Shimabukuro R, Yamaguchi S, et al. Laparoscopic splenectomy for portal hypertension. Hepatogastroenterology 2002;49:847–852
   PubMed Web of Science ®Google Scholar
• Kercher KW, Carbonell AM, Heniford BT, Matthews BD, Cunningham DM, Reindollar RW. Laparoscopic splenectomy reverses thrombocytopenia in patients with hepatitis C cirrhosis and portal hypertension. J Gastrointest Surg 2004;8:120–126
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Horiuchi A, Yoshida M, Yamamoto Y, Sugishita H, Kumagi T, Hiasa Y, Kawachi K. Significance of laparoscopic splenectomy in patients with hypersplenism. World J Surg 2007;31:549–555
   PubMed Web of Science ®Google Scholar
• Wong F. The use of TIPS in chronic liver disease. Ann Hepatol 2006;5:5–15
   PubMedGoogle Scholar
• Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109:4739–4741
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227–2236
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: Safety and efficacy. Br J Haematol 2013;161:411–423
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kanashima H, Nakao T, Ogawa Y, Hino M, Nakane T, Ohta T, Kumura T, Manabe M, Yamamura R, et al. Retrospective analysis of eltrombopag for the treatment of refractory primary immune thrombocytopenia in Japan. Rinsho Ketsueki 2013;54:444–450
   PubMedGoogle Scholar
• Kirito K, Komatsu N. Progression of bone marrow fibrosis with reticulin and collagen hyperplasia during treatment with the thrombopoietin receptor agonist romiplostim in a patient with immune thrombocytopenia. Rinsho Ketsueki 2013;54:295–299
   PubMedGoogle Scholar
• Michalska Z, Stalke P, Witczak-Malinowska K, Lakomy EA, Sikorska K, Radowska D, Stolarczyk J, Trocha H. Autoimmune reactions in HBV and HCV. Med Sci Monit 2001;7 Suppl 1:175–180
   PubMedGoogle Scholar
• Kajihara M, Kato S, Okazaki Y, Kawakami Y, Ishii H, Ikeda Y, Kuwana M. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003;37:1267–1276
   PubMed Web of Science ®Google Scholar
• Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: Guidelines for prevention and management. Intern Med J 2007;37:705–712
   PubMed Web of Science ®Google Scholar
• Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, Zhang M. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl 2006;12:253–258
   PubMed Web of Science ®Google Scholar
• Page LK, Psaila B, Provan D, Michael Hamilton J, Jenkins JM, Elish AS, Lesser ML, Bussel JB. The immune thrombocytopenic purpura (ITP) bleeding score: Assessment of bleeding in patients with ITP. Br J Haematol 2007;138:245–248
   PubMed Web of Science ®Google Scholar
• Yang CH, Wu TS, Chiu CT. Chronic hepatitis B reactivation: A word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol 2007;157:587–590
   PubMed Web of Science ®Google Scholar
• Luo SQ, Zhang LX. AASLD practice guidelines: chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2007;15:477–480
   PubMedGoogle Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009;50:661–662
   PubMed Web of Science ®Google Scholar
• Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000;31:1005–1013
   PubMed Web of Science ®Google Scholar
• Pradella P, Bonetto S, Turchetto S, Uxa L, Comar C, Zorat F, De Angelis V, Pozzato G. Platelet production and destruction in liver cirrhosis. J Hepatol 2011;54:894–900
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009;113:2386–2393
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168–186
   PubMed Web of Science ®Google Scholar
• Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013;58:1537–1547
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176–181
   PubMed Web of Science ®Google Scholar
• Meehan KR, Ericson SG, Tosteson TD, Mills LE. Quantitative assessment of colony growth and hematologic engraftment in patients undergoing high-dose chemotherapy and autologous bone marrow transplantation for breast cancer. Prog Clin Biol Res 1994;389:497–503
   PubMedGoogle Scholar
• Romero R, Kleinman RE. Thrombocytopenia associated with acute hepatitis B infection. Pediatrics 1993;91:150–152
   PubMed Web of Science ®Google Scholar
• Ibarra H, Zapata C, Inostroza J, Mezzano S, Riedemann S. Immune thrombocytopenic purpura associated with hepatitis A. Blut 1986;52:371–375
   PubMedGoogle Scholar
• Graber D, Giuliani D, Leevy CM, Morse BS. Platelet-associated IgG in hepatitis and cirrhosis. J Clin Immunol 1984;4:108–111
   PubMed Web of Science ®Google Scholar
• Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986;83:1627–1631
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: Assessment and preventive strategies. Ann Rheum Dis 2006;65:983–989
   PubMed Web of Science ®Google Scholar
• Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699–712
   PubMed Web of Science ®Google Scholar
• Sjogren MH, Hoofnagle JH, Waggoner JG. Effect of corticosteroid therapy on levels of antibody to hepatitis B core antigen in patients with chronic type B hepatitis. Hepatology 1987;7:582–585
   PubMed Web of Science ®Google Scholar
• Nouri-Aria KT, Hegarty JE, Alexander GJ, Eddleston AL, Williams R. Effect of corticosteroids on suppressor-cell activity in “autoimmune” and viral chronic active hepatitis. N Engl J Med 1982;307:1301–1304
   PubMed Web of Science ®Google Scholar
• Gregory PB, Knauer CM, Kempson RL, Miller R. Steroid therapy in severe viral hepatitis. A double-blind, randomized trial of methyl-prednisolone versus placebo. N Engl J Med 1976;294:681–687
   PubMed Web of Science ®Google Scholar
• Hansson BG, Riesbeck K, Nordenfelt E, Weiland O. Successful treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection explained by inhibitory effect on the immune response? Prog Clin Biol Res 1991;364:421–427
   PubMedGoogle Scholar
• Fujiwara K, Yokosuka O, Kojima H, Kanda T, Saisho H, Hirasawa H, Suzuki H. Importance of adequate immunosuppressive therapy for the recovery of patients with “life-threatening” severe exacerbation of chronic hepatitis B. World J Gastroenterol 2005;11:1109–1114
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Yasui S, Yonemitsu Y, Fukai K, Arai M, Imazeki F, Suzuki A, Suzuki H, Sadahiro T, Oda S, et al. Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol 2008;43:711–719
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Yasui S, Okitsu K, Yonemitsu Y, Oda S, Yokosuka O. The requirement for a sufficient period of corticosteroid treatment in combination with nucleoside analogue for severe acute exacerbation of chronic hepatitis B. J Gastroenterol 2010;45:1255–1262
   PubMed Web of Science ®Google Scholar
• Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Tien HF, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003;37:1320–1328
   PubMed Web of Science ®Google Scholar
• Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: A review of the problem. J Clin Oncol 1999;17:394–398
   PubMed Web of Science ®Google Scholar
• Bouchard MJ, Puro RJ, Wang L, Schneider RJ. Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. J Virol 2003;77:7713–7719
   PubMed Web of Science ®Google Scholar
• Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38:1282–1288
   PubMed Web of Science ®Google Scholar
• Bienkowska-Haba M, Patel HD, Sapp M. Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog 2009;5:e1000524
   Google Scholar
• Liu X, Zhao Z, Li Z, Xu C, Sun L, Chen J, Liu W. Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways. PLoS One 2012;7:e37277
   Google Scholar
• Pfefferle S, Schopf J, Kogl M, Friedel CC, Muller MA, Carbajo-Lozoya J, Stellberger T, von Dall'Armi E, Herzog P, Kallies S, et al. The SARS-coronavirus-host interactome: Identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog 2011;7:e1002331
   PubMed Web of Science ®Google Scholar
• Qing M, Yang F, Zhang B, Zou G, Robida JM, Yuan Z, Tang H, Shi PY. Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein. Antimicrob Agents Chemother 2009;53:3226–3235
   PubMed Web of Science ®Google Scholar
• Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med 2003;9:1138–1143
   PubMed Web of Science ®Google Scholar
• Bouchard MJ, Wang LH, Schneider RJ. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 2001;294:2376–2378
   PubMed Web of Science ®Google Scholar
• Broekemeier KM, Dempsey ME, Pfeiffer DR. Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J Biol Chem 1989;264:7826–7830
   PubMed Web of Science ®Google Scholar
• Xia WL, Shen Y, Zheng SS. Inhibitory effect of cyclosporine A on hepatitis B virus replication in vitro and its possible mechanisms. Hepatobiliary Pancreat Dis Int 2005;4:18–22
   PubMedGoogle Scholar
• Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, Iwamoto M, Nakajima S, Tsukuda S, Borroto-Esoda K, et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 2014;59:1726--1737
   PubMed Web of Science ®Google Scholar
• Dai MS, Kao WY, Shyu RY, Chao TY. Restoration of immunity and reactivation of hepatitis B virus after immunosuppressive therapy in a patient with severe aplastic anaemia. J Viral Hepat 2004;11:283–285
   PubMed Web of Science ®Google Scholar
• Campione E, Paterno EJ, Diluvio L, Bianchi L, Giorgetti G, Chimenti S. Combination of low-dosage cyclosporine and topical pimecrolimus in severe atopic dermatitis with chronic hepatitis B. Acta Derm Venereol 2008;88:74–75
   PubMed Web of Science ®Google Scholar
• Emilia G, Luppi M, Morselli M, Forghieri F, Potenza L, Torelli G. A possible role for low-dose cyclosporine in refractory immune thrombocytopenic purpura. Haematologica 2008;93:1113–1115
   PubMed Web of Science ®Google Scholar
• Zver S, Zupan IP, Cernelc P. Cyclosporin A as an immunosuppressive treatment modality for patients with refractory autoimmune thrombocytopenic purpura after splenectomy failure. Int J Hematol 2006;83:238–242
   PubMed Web of Science ®Google Scholar